Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.50 |
| ▸ | ULK1 | O75385 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.44 |
| ▸ | KDR | P35968 | 4/20 | 0.44 |
| ▸ | WEE1 | P30291 | 3/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | PAK4 | O96013 | 2/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | FYN | P06241 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | IGF1R | P08069 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13616150 | 0.86 | ULK1 (0.46) | ULK1SYKWEE1LCKIGF1R | |
| SCHEMBL13616147 | 0.83 | JAK1 (0.43) | AURKAJAK3AURKB | |
| SCHEMBL13616093 | 0.77 | RPS6KA6 (0.59) | FGFR1 | |
| SCHEMBL1203509 | 0.76 | PLK1 (0.55) | CDC7SYKROCK1KDRWEE1 | |
| SCHEMBL13616167 | 0.76 | CDK2 (0.57) | CDK9 | |
| SCHEMBL11976974 | 0.75 | RPS6KA6 (0.59) | KDRWEE1ALKAURKAJAK2 | |
| SCHEMBL2436329 | 0.75 | PLK1 (0.51) | CDC7ULK1SYKROCK1KDR | |
| SCHEMBL13616293 | 0.74 | CDK4 (0.60) | KDRWEE1ALKAURKAJAK2 | |
| SCHEMBL12894104 | 0.74 | PLK1 (0.50) | CDC7ULK1SYKROCK1KDR | |
| SCHEMBL29208311 | 0.74 | CDC7 (0.52) | CDC7ULK1SYKROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | CDC7 266/4885ULK1 467/4885SYK 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.